Neumora Therapeutics Inc. (NASDAQ:NMRA)’s traded shares stood at 0.74 million during the last session, with the company’s beta value hitting 3.63. At the close of trading, the stock’s price was $12.03, to imply an increase of 1.69% or $0.2 in intraday trading. The NMRA share’s 52-week high remains $21.00, putting it -74.56% down since that peak but still an impressive 30.76% since price per share fell to its 52-week low of $8.33. The company has a valuation of $1.93B, with an average of 0.51 million shares in intraday trading volume over the past 10 days and average of 802.73K shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Neumora Therapeutics Inc. (NMRA), translating to a mean rating of 1.00. Of 3 analyst(s) looking at the stock, 0 analyst(s) give NMRA a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 3 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -0.4.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Neumora Therapeutics Inc. (NASDAQ:NMRA) trade information
After registering a 1.69% upside in the last session, Neumora Therapeutics Inc. (NMRA) has traded red over the past five days. The 5-day price performance for the stock is 15.01%, and 7.70% over 30 days. With these gigs, the year-to-date price performance is -29.44%. Short interest in Neumora Therapeutics Inc. (NASDAQ:NMRA) saw shorts transact 9.98 million shares and set a 20.04 days time to cover.
The extremes give us $20 and $29 for target low and target high price respectively. As such, NMRA has been trading -141.06% off suggested target high and -66.25% from its likely low.
Neumora Therapeutics Inc. (NMRA) estimates and forecasts
Looking at statistics comparing Neumora Therapeutics Inc. share performance against respective industry, we note that the company has outperformed competitors. Neumora Therapeutics Inc. (NMRA) shares are -20.49% down over the last 6 months, with its year-to-date growth rate higher than industry average at 58.40% against 17.20%. Revenue is forecast to grow 64.90% this quarter before jumping 46.50% for the next one.
NMRA Dividends
Neumora Therapeutics Inc. has its next earnings report out on 2024-Aug-06. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Neumora Therapeutics Inc. (NASDAQ:NMRA)’s Major holders
Neumora Therapeutics Inc. insiders hold 28.05% of total outstanding shares, with institutional holders owning 61.25% of the shares at 85.13% float percentage. In total, 61.25% institutions holds shares in the company.
We also have Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF as the top two Mutual Funds with the largest holdings of the Neumora Therapeutics Inc. (NMRA) shares. Going by data provided on Jun 30, 2024 , Vanguard Total Stock Market Index Fund holds roughly 2.39 shares. This is just over 1.49% of the total shares, with a market valuation of $28.76 million. Data from the same date shows that the other fund manager holds a little less at 2.3, or 1.44% of the shares, all valued at about 27.67 million.
